AR066782A1 - Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida - Google Patents
Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solidaInfo
- Publication number
- AR066782A1 AR066782A1 ARP080102286A ARP080102286A AR066782A1 AR 066782 A1 AR066782 A1 AR 066782A1 AR P080102286 A ARP080102286 A AR P080102286A AR P080102286 A ARP080102286 A AR P080102286A AR 066782 A1 AR066782 A1 AR 066782A1
- Authority
- AR
- Argentina
- Prior art keywords
- muscle relaxant
- neurotoxic component
- botulinic
- oxine
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Proceso para proporcionar un relajante muscular a temperaturas superiores a 20°C, donde dicho relajante muscular es una composicion seca solida que comprende el componente neurotoxico de toxina botulínica libre de proteínas formadoras de complejos. Reivindicacion 9: El proceso de acuerdo con cualquiera de las reivindicaciones precedentes, donde la composicion es un liofilizado del componente neurotoxico de toxina botulínica. Reivindicacion 10: El proceso de acuerdo con cualquiera de las reivindicaciones precedentes, donde la composicion comprende además sacarosa y/o seroalbumina humana. Reivindicacion 11: El proceso de acuerdo con cualquiera de las reivindicaciones precedentes, donde la composicion comprende además por lo menos un componente seleccionado del grupo formado por un crioprotector, un estabilizante, un buffer del pH, un excipiente, que no es sacarosa ni seroalbumina humana, respectivamente, y sus mezclas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93262407P | 2007-06-01 | 2007-06-01 | |
EP07010912A EP1997509A1 (en) | 2007-06-01 | 2007-06-01 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
US99885807P | 2007-10-12 | 2007-10-12 | |
EP07020025A EP2048156A1 (en) | 2007-10-12 | 2007-10-12 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066782A1 true AR066782A1 (es) | 2009-09-09 |
Family
ID=40074591
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102287A AR066783A1 (es) | 2007-06-01 | 2008-05-30 | Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica |
ARP080102286A AR066782A1 (es) | 2007-06-01 | 2008-05-30 | Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102287A AR066783A1 (es) | 2007-06-01 | 2008-05-30 | Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica |
Country Status (15)
Country | Link |
---|---|
US (2) | US20090010965A1 (es) |
EP (2) | EP2170375A1 (es) |
JP (2) | JP2010529000A (es) |
KR (2) | KR20100020972A (es) |
CN (2) | CN101687018A (es) |
AR (2) | AR066783A1 (es) |
AU (2) | AU2008256419A1 (es) |
BR (2) | BRPI0812245A2 (es) |
CA (2) | CA2686637A1 (es) |
IL (2) | IL202129A0 (es) |
MX (2) | MX2009012570A (es) |
RU (1) | RU2009149604A (es) |
TW (2) | TW200902050A (es) |
WO (2) | WO2008145358A1 (es) |
ZA (2) | ZA200907874B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
RU2011125775A (ru) | 2008-12-31 | 2013-02-10 | Реванс Терапьютикс, Инк. | Составы на основе ботулотоксина для инъекции |
US20100184685A1 (en) * | 2009-01-19 | 2010-07-22 | Zavala Jr Gerardo | Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein |
WO2010094463A1 (en) * | 2009-02-19 | 2010-08-26 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for manufacturing highly pure neurotoxin |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
CA2757637C (en) * | 2009-04-27 | 2017-10-24 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities |
KR102328155B1 (ko) | 2009-06-25 | 2021-11-17 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
MX2012004703A (es) * | 2009-10-21 | 2012-06-08 | Revance Therapeutics Inc | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
SG10201605324PA (en) * | 2011-03-31 | 2016-08-30 | Medy Tox Inc | Lyophilized preparation of botulinum toxin |
KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
KR101357999B1 (ko) * | 2012-03-20 | 2014-02-03 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
EP3236939B1 (en) * | 2014-12-23 | 2020-04-01 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin prefilled container |
US10406290B2 (en) | 2015-02-03 | 2019-09-10 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled plastic syringe |
EP3070539A1 (fr) * | 2015-03-17 | 2016-09-21 | Omega SA | Montre-bracelet comprenant un cadran muni d'index lumineux |
WO2018038301A1 (en) * | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
MX2020014330A (es) * | 2018-12-26 | 2021-03-09 | Caregen Co Ltd | Composicion para relajacion muscular. |
WO2020138674A1 (ko) | 2018-12-26 | 2020-07-02 | (주)케어젠 | 근육 이완용 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US20030224020A1 (en) * | 2002-05-31 | 2003-12-04 | Zabudkin Alexander F. | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
CN101005853B (zh) * | 2004-07-26 | 2011-05-04 | 莫茨药物股份两合公司 | 包含肉毒杆菌神经毒素的治疗组合物 |
DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
CA2612205C (en) * | 2005-06-17 | 2012-07-10 | Merz Pharma Gmbh & Co. Kgaa | Apparatus and process for the fermentative production of biological active compounds |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
-
2008
- 2008-05-28 CN CN200880018442A patent/CN101687018A/zh active Pending
- 2008-05-28 WO PCT/EP2008/004253 patent/WO2008145358A1/en active Application Filing
- 2008-05-28 MX MX2009012570A patent/MX2009012570A/es not_active Application Discontinuation
- 2008-05-28 BR BRPI0812245-8A2A patent/BRPI0812245A2/pt not_active IP Right Cessation
- 2008-05-28 EP EP08758836A patent/EP2170375A1/en not_active Withdrawn
- 2008-05-28 JP JP2010509731A patent/JP2010529000A/ja active Pending
- 2008-05-28 RU RU2009149604/15A patent/RU2009149604A/ru not_active Application Discontinuation
- 2008-05-28 KR KR1020097026300A patent/KR20100020972A/ko not_active Application Discontinuation
- 2008-05-28 AU AU2008256419A patent/AU2008256419A1/en not_active Abandoned
- 2008-05-28 AU AU2008256418A patent/AU2008256418A1/en not_active Abandoned
- 2008-05-28 BR BRPI0812322-5A2A patent/BRPI0812322A2/pt not_active IP Right Cessation
- 2008-05-28 MX MX2009012990A patent/MX2009012990A/es not_active Application Discontinuation
- 2008-05-28 KR KR1020097026298A patent/KR20100020971A/ko not_active Application Discontinuation
- 2008-05-28 WO PCT/EP2008/004254 patent/WO2008145359A1/en active Application Filing
- 2008-05-28 CN CN200880018452A patent/CN101720331A/zh active Pending
- 2008-05-28 EP EP08758837A patent/EP2164861A1/en not_active Withdrawn
- 2008-05-28 JP JP2010509730A patent/JP2010528999A/ja active Pending
- 2008-05-28 CA CA002686637A patent/CA2686637A1/en not_active Abandoned
- 2008-05-28 CA CA002686642A patent/CA2686642A1/en not_active Abandoned
- 2008-05-29 US US12/154,982 patent/US20090010965A1/en not_active Abandoned
- 2008-05-29 US US12/154,983 patent/US20090028906A1/en not_active Abandoned
- 2008-05-30 TW TW097120348A patent/TW200902050A/zh unknown
- 2008-05-30 AR ARP080102287A patent/AR066783A1/es not_active Application Discontinuation
- 2008-05-30 AR ARP080102286A patent/AR066782A1/es not_active Application Discontinuation
- 2008-05-30 TW TW097120349A patent/TW200914039A/zh unknown
-
2009
- 2009-11-10 ZA ZA2009/07874A patent/ZA200907874B/en unknown
- 2009-11-10 ZA ZA2009/07875A patent/ZA200907875B/en unknown
- 2009-11-15 IL IL202129A patent/IL202129A0/en unknown
- 2009-11-15 IL IL202130A patent/IL202130A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101687018A (zh) | 2010-03-31 |
AU2008256419A1 (en) | 2008-12-04 |
CN101720331A (zh) | 2010-06-02 |
TW200902050A (en) | 2009-01-16 |
AU2008256418A1 (en) | 2008-12-04 |
US20090028906A1 (en) | 2009-01-29 |
MX2009012570A (es) | 2010-03-15 |
JP2010529000A (ja) | 2010-08-26 |
BRPI0812322A2 (pt) | 2014-11-25 |
CA2686642A1 (en) | 2008-12-04 |
ZA200907874B (en) | 2011-03-30 |
RU2009149604A (ru) | 2011-07-20 |
EP2170375A1 (en) | 2010-04-07 |
MX2009012990A (es) | 2010-04-01 |
TW200914039A (en) | 2009-04-01 |
WO2008145358A1 (en) | 2008-12-04 |
US20090010965A1 (en) | 2009-01-08 |
AR066783A1 (es) | 2009-09-09 |
BRPI0812245A2 (pt) | 2014-10-21 |
IL202130A0 (en) | 2010-06-16 |
KR20100020971A (ko) | 2010-02-23 |
EP2164861A1 (en) | 2010-03-24 |
WO2008145359A1 (en) | 2008-12-04 |
KR20100020972A (ko) | 2010-02-23 |
ZA200907875B (en) | 2010-11-24 |
CA2686637A1 (en) | 2008-12-04 |
IL202129A0 (en) | 2010-06-16 |
JP2010528999A (ja) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066782A1 (es) | Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida | |
UY37495A (es) | Dinucleótidos cíclicos como agonistas de sting | |
DK2158319T3 (da) | Knoglemålrettet alkalisk fosfatase, kits og fremgangsmåder til anvendelse deraf | |
DK1866414T3 (da) | Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf. | |
ATE477321T1 (de) | Aviäre telomerase reverse transkriptase | |
BRPI0516857A (pt) | dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico | |
AR069860A1 (es) | Metodo para purificar un anticuerpo cd20 | |
CR9657A (es) | Crystaline forms of 4-methyl-n-(3(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl)3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | |
BRPI0813237B8 (pt) | composto, método para preparar o composto, medicamento, e, uso do composto | |
BRPI0721503A8 (pt) | composições e métodos para tratamento de um poço bloqueado por água | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
GT200600227A (es) | Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas | |
EA201000327A1 (ru) | Белок | |
ATE512228T1 (de) | Induzierbare expressionssysteme | |
BRPI0611820B8 (pt) | método de identificar uma infecção por e. canis ou e. chaffeensis | |
BR112017008149A2 (pt) | seleção de componentes da matriz extracelular e/ou proteínas matricelulares para a viabilidade e retenção melhoradas da célula após a criopreservação | |
BRPI0606358A2 (pt) | uso de pelo menos um aminoditiol, processo e kit para a deformação permanente dos cabelos e aminotióis | |
NZ752705A (en) | Dna-binding protein using ppr motif, and use thereof | |
ATE523572T1 (de) | Fluorchemische urethanverbindungen und damit hergestellte wässrige zusammensetzung | |
AR062123A1 (es) | Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus | |
AR101147A1 (es) | Composiciones y métodos que comprenden una variante de xilanasa | |
ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
AR101715A1 (es) | Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis | |
NO20034278L (no) | Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner | |
BRPI0600403A (pt) | condensados que contêm grupos ácidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |